Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 15CNS 6Gastrointestinal 5Gynecologic 4Tumor-Agnostic 2Thoracic 2Sarcoma 2Other solid neoplasm 2Head & Neck 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Gliosarcoma 1Glioblastoma 1Brain Neoplasms 13rd Line GIST 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × NVP-BKM120 × Sarcoma × Clear all
NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Novartis

Phase 1 Completed
60 enrolled
Sarcoma

3rd Line GIST

NCT01870726 2018-05-30

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Novartis

Phase 1/2 Terminated
43 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡